Deep Brain Stimulation for Spinocerebellar Ataxia
A legfontosabb adatok
- Ki végzi
- University of California, San Francisco
- Hol
- San Francisco (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 5 fő, tervezett
- Kezdés
- 2026. ápr. 27.
- Várható befejezés
- 2031. márc.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Deep Brain Stimulation (DBS)
- A regiszteradat frissítve
- 2026. július 13.
Ki vehet részt
- Életkor
- 21 év – 89 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- A diagnosis of SCA6 by a Movement Disorders specialist following established criteria recommended by the Movement Disorders Society
- A positive genetic test for SCA6
- A total scale ≥ 8 on the Scale of the Assessment and Rating of Ataxia (SARA) rating scale
- Ability to walk with or without support (score < 8 on the 'gait' subsection of the SARA rating scale)
- Age ≥ 21 years and < 89 years
- Ability to give informed consent for the study
- Be able to understand the study protocol
Ki nem vehet részt
- History of previously implanted neurostimulators, pacemakers, defibrillators, or metallic head implants
- Coagulopathy, uncontrolled epilepsy, or other medical condition considered to place the patient at elevated risk for surgical complications. Presence of a concomitant medical condition that, in the investigator's opinion, may interfere with the study participation or gait/balance, for example, severe arthritis
- Requirement of diathermy, electroconvulsive therapy, or transcranial magnetic stimulation
- Severe cognitive impairment or dementia, defined as a score < 21 on the Montreal Cognitive Assessment (MoCA)
- Evidence of ataxia due to other etiologies, including but not limited to:; Genetic/inherited disorders other than SCA6; Acquired causes: tramautic brain injury, multiple sclerosis, paraneplastic cerebellar degeneration, infections or post-infectious cerebellitis, autoimmune ataxias (e.g., anti-GAD, gluten ataxia); Toxic/metabolic causes: alcoholic cerebellar degeneration, vitamin deficiencies; Structural, vascular, or neoplastic causes: cerebellar stroke, tumors, congenital malformations; Suspected multiple system atrophy-cerebellar type (MSA-C)
- The presence of active and untreated psychiatric illness, severe depression (Beck Depression Inventory ≥ 21), or personality disorder at the discretion of the study team
- Presence of a concominant medical condition that, in the investigator's opinion, may interfere with the study participation or gait/balance, for example, severe arthritis
- Refractory Epilepsy
- Inability or unwillingness to comply with the study protocol
- Pregnancy or lactation
- Active suicidal ideation, defined as fined as a "Yes" response to questions #2-5 on the Columbia Suicide Severity Rating Scale, C-SSRS
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 21 és 89 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- UCSF Weill Institute for NeurosciencesSan Francisco, Egyesült ÁllamokContact: Marta San Luciano Palenzuela, MD, PhDRésztvevőt keres
- University of California San FranciscoSan Francisco, Egyesült ÁllamokContact: Marta San Luciano Palenzuela, MD, PhDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to test the safety of placing Deep Brain Stimulators (DBS) in the cerebellum and using electrical stimulation of that part of the brain to treat symptoms related to the participants spinocerebellar ataxia. Five adults diagnosed with spinocerebellar ataxia type 6 (SCA6) with inadequate cerebellar symptom relief will be implanted with a Medtronic Percept Primary Cell Neurostimulator. The device will be implanted into the dentate nucleus, which is a structure located within the cerebellum that is responsible for controlling movement and balance.
A teljes eredeti leírásKevesebb
Specifically, the investigators will be using adaptive deep brain stimulation (aDBS), which analyzes brain signals and automatically adjusts the strength, timing, and pattern of stimulation according to the patient's needs at any given moment. This study will evaluate the feasibility, safety, and tolerability of aDBS in SCA6 patients.
A vizsgálat csoportja
- Adaptive Deep Brain Stimulation (aDBS)A vizsgált kezelés
One month after patients undergo DBS surgery in the cerebellum, conventional deep brain stimulation (cDBS) programming will begin to identify stimulation parameters (such as amplitude, contact, frequency, and pulse width) and ensure no adverse wide effects are witness. This phase also allows the study team to make sure device and electrode placement are working as intended. About nine months after implantation, the investigators will switch system settings over to aDBS to evaluate the feasibility, safety, and tolerability in the dentate nucleus of the cerebellum. Symptoms and side effects will be assessed by patients' self-reports, validated clinical scales, and wearable devices, which will be used to track movements and sleep data.
Kezelés: Deep Brain Stimulation (DBS)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Adaptive Deep Brain Stimulation Targeting the Dentate Nucleus to Treat Spinocerebellar Ataxia
- Kérdések a feltételekről
- Forrás: NCT07288437: ki vehet részt
- A regiszteradat frissítve
- 2026. július 13.